Mr Daniel Andrew Hilbrich, DO | |
32669 W Warren Rd, Ste 10, Garden City, MI 48135 | |
(734) 762-0500 | |
(734) 762-0530 |
Full Name | Mr Daniel Andrew Hilbrich |
---|---|
Gender | Male |
Speciality | Dermatology - Clinical & Laboratory Dermatological Immunology |
Location | 32669 W Warren Rd, Garden City, Michigan |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1760583538 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207NI0002X | Dermatology - Clinical & Laboratory Dermatological Immunology | 5101013288 (Michigan) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Daniel Andrew Hilbrich, DO 32669 W Warren Rd, Ste 10, Garden City, MI 48135 Ph: (734) 762-0500 | Mr Daniel Andrew Hilbrich, DO 32669 W Warren Rd, Ste 10, Garden City, MI 48135 Ph: (734) 762-0500 |
News Archive
Researchers from the Molecular Mechanisms and Experimental Therapy in Oncology program of the Bellvitge Biomedical Research Institute and the Catalan Institute of Oncology, together with the Biodonostia Health Research Institute, among others, have published in Nutrients the results of a multicenter study that unveils a correlation between inflammatory and antioxidant diets and the risk of developing colorectal and breast cancer.
US Special Forces are funding a world first, breakthrough drug therapy for treating battle casualties that's being developed by James Cook University scientists in Australia.
Scientists at Columbia University, the University of California, San Diego (UCSD) and Harvard University have presented an alternative method to address the challenge of using significant variables to make useful predictions in areas such as complex disease.
New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's ixekizumab, an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, with significantly more patients achieving at least a 75 percent improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo at week 12.
› Verified 7 days ago
Chelsea K Duggan, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-421-3300 |